



## The Evolution of **Multiple Myeloma** Patient Management: Managing Today, Preparing for Tomorrow

### Faculty Biographies



**C. Ola Landgren, MD, PhD**

Chief, Myeloma Service  
Professor of Medicine  
Memorial Sloan Kettering Cancer Center  
New York, New York

C. Ola Landgren completed his medical degree and doctorate at Karolinska Institute in Stockholm, Sweden. His postdoctoral training included residencies at Nykoping Hospital in Sweden; fellowships in hematology and internal medicine at Karolinska University Hospital, and fellowship in medicine at the National Cancer Institute. He is board certified in hematology and internal medicine.

Dr. Landgren is one of the world leaders in the field of early treatment strategies and molecular- and cell-based monitoring of minimal residual disease (MRD) detection in multiple myeloma and its precursor states. He leads a translational research program at Memorial Sloan Kettering Cancer Center that is designed to discover new treatment paradigms integrating modern therapy and novel MRD assays. He has designed and led the definitive study showing that all multiple myeloma patients are preceded by a precursor stage. As part of his ongoing research program, Dr. Landgren is studying molecular mechanisms underlying the trajectory from precursor to full-blown multiple myeloma with the goal to develop treatment strategies aiming to delay, prevent, and ultimately define a cure for multiple myeloma

Dr. Landgren has published over 250 peer-reviewed publications and he is a frequently invited speaker at national and international hematology conferences. He serves on several research committees and editorial boards for scientific journals.